论文部分内容阅读
2015年2月6日,加拿大卫生部向医疗保健专业人士致信,提示关于富马酸二甲酯的进展性多灶性脑白质病(PML)风险。在加拿大,富马酸二甲酯(商品名Tecfidera)批准用于治疗复发缓解型多发性硬化(MS),目的是降低临床恶化频率,延缓残疾进展。PML是一种机会性脑部病毒感染,由John Cunningham(JC)病毒引起,通常发生于免疫功能不全的患者中,可导致重度残疾或死亡。一些PML症状与MS相似,包括身体一侧进行性虚弱或四肢笨拙、视力模糊、思维方式改变、记忆和定向改变及性格改变。
On February 6, 2015, Health Canada sent a letter to healthcare professionals about the risk of progressive multifocal leukoencephalopathy (PML) with dimethyl fumarate. In Canada, dimethyl fumarate (Tecfidera) is approved for the treatment of relapsing-remitting multiple sclerosis (MS) in order to reduce the frequency of clinical deterioration and delay the progression of disability. PML is an opportunistic brain virus infection caused by the John Cunningham (JC) virus and usually occurs in immunocompromised patients and can result in severe disability or death. Some symptoms of PML are similar to those of MS, including progressive weakness or clumsiness in the body, blurred vision, changes in modes of thinking, changes in memory and orientation, and personality changes.